How did profit growth compare to revenue growth?

Revenue grew 44% to ₹9,595 lakhs, but profit grew only 16.6% to ₹1,081 lakhs. The gap suggests costs rose faster than sales.

Was the market surprised by these numbers?

No. The analyst rationale states the core information was already disclosed in prior filings. This board outcome was a formal confirmation.

What dividend did the board recommend?

A final dividend of ₹5 per share. For a company with a ₹210 crore market capitalization, this represents a notable cash distribution.

What else did the board approve?

Routine governance items, including auditor appointments and notice for the annual general meeting. These are procedural and carry no investment signal.

Earnings · Pharmaceuticals · Micro cap

BDH Industries posts 44% revenue growth, ₹5 dividend

FY26 audited results are a confirmation, not a catalyst. Profit growth of 16.6% lags the top-line surge.

— 1 earlier story on BDH Industries Ltd. →

MBIND By Tipsheet Editorial 21 May 2026 · 7:15 PM IST Verify on BSE · NSE

Mkt cap₹259 cr

P/E23.96×

ROE13.49%

Debt / eq.0.01

Div yld1.15%

₹9,595 lakhs FY26 standalone revenue, up 44% year-on-year.

What's new

Board approved audited FY26 standalone results: revenue grew 44% to ₹9,595 lakhs.
PAT grew 16.6% to ₹1,081 lakhs for the year.
Final dividend of ₹5 per share recommended.

Why this matters

Revenue grew faster than profit, signaling margin pressure. The ₹5 dividend is a meaningful return for a ₹210 crore market cap, but the filing contains no new information beyond prior disclosures.

What we're watching

Whether FY27 margins recover to let profit growth catch revenue.
Sustainability of the 44% revenue growth rate.
The dividend payout ratio relative to reported profit.

The full read

BDH Industries' FY26 results are a confirmation. The nano-cap pharma's standalone revenue hit ₹9,595 lakhs, a 44% year-on-year jump. Profit grew too. Only by 16.6%, to ₹1,081 lakhs. That lag between top-line and bottom-line growth is the key takeaway. It points to margin compression during the year. The board signed off on these numbers and recommended a ₹5 per share dividend. For a ₹210 crore market cap, the payout is material. But none of this is new. The numbers were disclosed in prior filings. What changes from here is whether FY27 margins improve, allowing profit to catch up to revenue.

Questions answered

How did profit growth compare to revenue growth?: Revenue grew 44% to ₹9,595 lakhs, but profit grew only 16.6% to ₹1,081 lakhs. The gap suggests costs rose faster than sales.
Was the market surprised by these numbers?: No. The analyst rationale states the core information was already disclosed in prior filings. This board outcome was a formal confirmation.
What dividend did the board recommend?: A final dividend of ₹5 per share. For a company with a ₹210 crore market capitalization, this represents a notable cash distribution.
What else did the board approve?: Routine governance items, including auditor appointments and notice for the annual general meeting. These are procedural and carry no investment signal.

Mentioned: BDH Industries · ₹5 per share dividend · FY26 standalone results

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

BDH Industries Ltd.

Pharmaceuticals

₹211 cr

P/E 19.53×

Latest quarter · Mar 2026

Sales₹29 cr

Net profit₹3 cr

Op. margin+14.5%

EPS₹5.00

Strength & growth

Debt / equity0.01×

Current ratio3.95×

Sales CAGR+7.6%

EPS CAGR+12.3%

Story so far

All notes on MBIND →

21 May 2026 · 7:15 PM IST BDH Industries posts 44% revenue growth, ₹5 dividend
46d ago BDH Industries posts 44% revenue growth, but profit didn't follow.